专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007143538A3 PIKE-A ENHANCES INFECTION BY MYXOMA VIRUS 审中-公开
标题翻译： PIKE-A通过MYXOMA病毒增强感染
公开(公告)号：WO2007143538A3
公开(公告)日：2008-02-21
申请号：PCT/US2007070199
申请日：2007-06-01
申请人： ROBARTS RES INST , MCFADDEN GRANT , WERDEN STEVEN
发明人： MCFADDEN GRANT , WERDEN STEVEN
IPC分类号： C12N15/00
CPC分类号： A61K35/76 , A61K38/46 , C12Y306/05 , A61K2300/00
摘要： Cellular Akt activation is increased by transducing an Akt-containing cell with a vector that expresses exogenous PIKE-A (PIl 3 -kinase enhancer activating Akt) in the cell. Expression of PIKE-A increases the susceptibility of cancer cells to myxoma virus infection. Cancer is treated by administering a vector that infects cancer cells and expresses exogenous PIKE-A; and a myxoma virus. Cancer is treated by taking cancer cells from a subject, transducing them ex vivo with a vector that expresses exogenous PIKE-A in the cells, treating the transduced cells with a myxoma virus, and then returning the transduced cells to the subject. Alternatively, myxoma virus can be administered to the patient after the transduced cells have been returned to the patient. The susceptibility of cells to infection with a myxoma virus can be determined by assaying for PIKE-A expression. Cellular expression of PIKE-A in the cell indicates susceptibility to myxoma virus infection.
摘要翻译：通过用表达外源PIKE-A（PI3-3激酶增强子激活Akt）的载体转导含Akt的细胞来增加细胞Akt活化。 PIKE-A的表达增加了癌细胞对粘液瘤病毒感染的敏感性。通过施用感染癌细胞并表达外源性PIKE-A的载体来治疗癌症; 和粘液瘤病毒。通过从受试者中摄取癌细胞来治疗癌症，用在细胞中表达外源性PIKE-A的载体离体转染它们，用粘液瘤病毒处理转导的细胞，然后将转导的细胞返回到受试者。或者，在转导的细胞已经返回到患者之后，可以向患者施用粘液瘤病毒。可以通过测定PIKE-A表达来确定细胞对粘液瘤病毒感染的易感性。细胞中PIKE-A的细胞表达表明对粘液瘤病毒感染的敏感性。

2. 发明申请

WO2013123305A1 MODULATORS OF ACYL-COA LYSOCARDIOLIPIN ACYLTRANSFERASE 1 ( ALCAT1) AND USES THEREOF 审中-公开
标题翻译： ACYL-COA LYSOCARDIOLIPIN ACYLTRANSFERASE 1（ALCAT1）的调节剂及其用途
公开(公告)号：WO2013123305A1
公开(公告)日：2013-08-22
申请号：PCT/US2013/026311
申请日：2013-02-15
申请人： THE PENN STATE RESEARCH FOUNDATION
发明人： SHI, Yuguang
IPC分类号： A61K38/00
CPC分类号： C07K16/40 , A61K38/1709 , A61K38/46 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/76 , C12N15/1137 , C12N2310/111 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , C12Y306/05
摘要： Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCATl ) expression, function or activity are provided. In particular, inhibitors of ALCATl are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCATl modulators are provided.
摘要翻译：提供了酰基辅酶A溶血卵磷脂转移酶1（ALCAT1）表达，功能或活性的调节剂的组成。特别地，ALCAT1的抑制剂可用于治疗代谢疾病，心脏病和一般与线粒体功能障碍相关的疾病。提供了鉴定新型ALCAT1调节剂的方法。

3. 发明申请

WO2016080608A1 COMPOSITIONS COMPRISING A MITOFUSIN INHIBITOR FOR PROMOTING CELL REPROGRAMMING AND A USE THEREOF 审中-公开
标题翻译：包含用于促进细胞代谢的麻醉抑制剂的组合物及其用途
公开(公告)号：WO2016080608A1
公开(公告)日：2016-05-26
申请号：PCT/KR2015/004067
申请日：2015-04-23
申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
发明人： CHO, Yee Sook , SON, Myung Jin , KWON, You Jeong
IPC分类号： C12N5/02 , C12N5/074 , C07K16/40
CPC分类号： C12N5/0696 , C12N15/1137 , C12N2310/14 , C12N2310/531 , C12N2500/02 , C12N2501/65 , C12N2501/73 , C12N2501/998 , C12N2506/02 , C12N2510/00 , C12Y306/05
摘要： The present invention relates to a composition comprising a repressor of mitofusin gene expression, an inhibitor of mitofusin protein activity, or a mixture thereof as an active ingredient for promoting reprogramming a differentiated cell into a pluripotent stem cell, and a use thereof. The composition according to the present invention increases the efficiency of reprogramming as well as reduces the time required for reprogramming to produce pluripotent stem cells. Therefore, the present composition can be beneficially used to develop the production technology of high efficiency pluripotent stem cell and secure a large-scale culture system. Further, the present composition can be beneficially used to maintain pluripotent stem cells and screen the compounds capable of promoting the reprogramming into pluripotent stem cells.
摘要翻译：本发明涉及一种组合物，其包含mitofusin基因表达的阻遏物，mitofusin蛋白活性的抑制剂或其混合物作为促进将分化的细胞重编程为多能干细胞的活性成分及其用途。根据本发明的组合物提高了重新编程的效率，并且减少了重新编程产生多能干细胞所需的时间。因此，本发明的组合物可以有利地用于开发高效多能干细胞的生产技术并确保大规模的培养体系。此外，本发明的组合物可有利地用于维持多能干细胞并筛选能够促进重编程成多能干细胞的化合物。

4. 发明申请

WO2015015306A3 METHOD FOR TARGETING VASCULAR RHOJ FOR INHIBITING TUMOR ANGIOGENESIS 审中-公开
标题翻译：用于抑制肿瘤血管生成的血管内皮生长因子的方法
公开(公告)号：WO2015015306A3
公开(公告)日：2015-07-16
申请号：PCT/IB2014002314
申请日：2014-04-29
申请人： KOREA ADVANCED INST SCI & TECH , KOH GOU YOUNG
发明人： KOH GOU YOUNG , KIM CHAN , YANG HANSEUL , HEO WON DO , KIM INJUNE , JON SANGYONG , UEMURA AKIYOSHI
IPC分类号： A61K38/17 , A61K38/00 , A61P35/00
CPC分类号： C12N15/1137 , A61K9/1271 , A61K31/661 , A61K31/7088 , A61K33/24 , A61K45/06 , C12N2310/14 , C12N2320/31 , C12Y306/05 , A61K2300/00
摘要： The present application describes a method of inhibiting tumor growth including contacting the tumor with a compound that inhibits activity of RhoJ protein.
摘要翻译：本申请描述了抑制肿瘤生长的方法，包括使肿瘤与抑制RhoJ蛋白活性的化合物接触。

5. 发明申请

WO2016049568A1 METHODS AND COMPOSITIONS FOR INHIBITION OF RAS 审中-公开
标题翻译：用于抑制RAS的方法和组合物
公开(公告)号：WO2016049568A1
公开(公告)日：2016-03-31
申请号：PCT/US2015/052437
申请日：2015-09-25
申请人： ARAXES PHARMA LLC
发明人： LI, Liansheng , FENG, Jun , LONG, Yun, Oliver , REN, Pingda , LIU, Yi
IPC分类号： C07D229/00
CPC分类号： C07D471/04 , A61K9/0019 , A61K9/0053 , A61K31/517 , A61K45/06 , C07D239/94 , C07D239/95 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C12N9/14 , C12Y306/05
摘要： Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer.
摘要翻译：提供Ras蛋白抑制剂，调节Ras蛋白活性的方法，以及Ras蛋白介导的病症治疗方法。描述了用化合物调节K-Ras，H-Ras或N-Ras突变蛋白的活性的方法。可以治疗的疾病包括癌症，如血液癌症，胰腺癌，MYH相关性息肉病，结肠直肠癌或肺癌。

6. 发明申请

WO2014011210A1 AAV-MEDIATED GENE THERAPY FOR RPGR X-LINKED RETINAL DEGENERATION 审中-公开
标题翻译： AAV介导的基因治疗用于RPGR X连锁的肾素变性
公开(公告)号：WO2014011210A1
公开(公告)日：2014-01-16
申请号：PCT/US2013/022628
申请日：2013-01-23
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , THE UNIVERSITY OF FLORIDA
发明人： BELTRAN, William, A. , AGUIRRE, Gustavo, D. , JACOBSON, Samuel, G. , CIDECIYAN, Artur, V. , LEWIN, Alfred, S. , BOYE, Sanford, L. , HAUSWIRTH, William, W. , DENG, Wen-Tao
IPC分类号： A61K48/00
CPC分类号： A61K38/46 , A61K38/1709 , A61K38/185 , A61K48/00 , A61K48/005 , C07K14/4702 , C12N15/86 , C12N2750/14143 , C12N2830/008 , C12Y306/05
摘要： Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with retinitis pigmentosa and x- linked retinitis pigmentosa in a subject. The methods include administering to said subject an effective concentration of a composition comprising a recombinant adeno -associated virus (AAV) carrying a nucleic acid sequence encoding a normal retinitis pigmentosa GTPase regulator (RPGR gene), or fragment thereof, under the control of regulatory sequences which express the product of the gene in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier.
摘要翻译：本文描述的是预防，阻止视力丧失进展或改善与受影响的色素性视网膜炎和色素性色素变性相关的其它病症的方法。所述方法包括向所述受试者施用有效浓度的组合物，所述组合物包含重组腺相关病毒（AAV），所述重组腺相关病毒（AAV）在调节序列的控制下携带编码正常视网膜色素变性GTP酶调节蛋白（RPGR基因）或其片段的核酸序列其表达该受试者的感光细胞中的基因的产物和药学上可接受的载体。

7. 发明申请

WO2015015306A2 METHOD FOR TARGETING VASCULAR RHOJ FOR INHIBITING TUMOR ANGIOGENESIS 审中-公开
标题翻译：靶向血管生成抑制肿瘤血管生成的方法
公开(公告)号：WO2015015306A2
公开(公告)日：2015-02-05
申请号：PCT/IB2014/002314
申请日：2014-04-29
申请人： KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KAIST) , KOH, Gou, Young
发明人： KOH, Gou, Young , KIM, Chan , YANG, Hanseul , HEO, Won, Do , KIM, Injune , JON, Sangyong , UEMURA, Akiyoshi
CPC分类号： C12N15/1137 , A61K9/1271 , A61K31/661 , A61K31/7088 , A61K33/24 , A61K45/06 , C12N2310/14 , C12N2320/31 , C12Y306/05 , A61K2300/00
摘要： The present application describes a method of inhibiting tumor growth including contacting the tumor with a compound that inhibits activity of RhoJ protein.
摘要翻译：本申请描述了抑制肿瘤生长的方法，包括使肿瘤与抑制RhoJ蛋白活性的化合物接触。

8. 发明申请

WO2013191906A1 OPTIMIZATION OF EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN MxA PROTEIN IN E. COLI 审中-公开
标题翻译：重组人类MxA蛋白在大肠杆菌中的表达和纯化优化
公开(公告)号：WO2013191906A1
公开(公告)日：2013-12-27
申请号：PCT/US2013/044244
申请日：2013-06-05
申请人： RAPID PATHOGEN SCREENING, INC.
发明人： VANDINE, Robert W. , SAMBURSKY, Robert P. , BABU, Uma Mahesh , NAGATA, Kyosuke
IPC分类号： C12N15/63 , C12N15/12 , C12Q1/68 , C12Q1/00
CPC分类号： A61K38/46 , C12N9/14 , C12N9/16 , C12Y301/04 , C12Y306/05 , G01N33/56983
摘要： Full length MxA constructs and truncated MxA constructs produce human MxA protein in E. coli. The full length MxA and truncated MxA constructs are preferably E. coli codon-optimized to optimize the amount of protein made using the constructs. T5 or T7 promoters can each be used in combination with either the full length MxA or the truncated MxA constructs. In one preferred embodiment, the MxA protein produced by the full length MxA or truncated MxA constructs is used in a control prep or external control. In other preferred embodiments, the MxA protein is used as a therapeutic.
摘要翻译：全长MxA构建体和截短的MxA构建体在大肠杆菌中产生人MxA蛋白。全长MxA和截短的MxA构建体优选是经密码子优化的E.coli，以优化使用构建体制备的蛋白质的量。 T5或T7启动子各自可以与全长MxA或截短的MxA构建体组合使用。在一个优选实施方案中，由全长MxA或截短的MxA构建体产生的MxA蛋白用于对照制备或外部对照。在其它优选的实施方案中，MxA蛋白用作治疗剂。

9. 发明申请

WO2009076966A3 RHOC-BASED IMMUNOTHERAPY 审中-公开
标题翻译：基于RHOC的免疫治疗
公开(公告)号：WO2009076966A3
公开(公告)日：2009-08-20
申请号：PCT/DK2008050324
申请日：2008-12-18
申请人： RHOVAC APS , ANDERSEN MADS HALD , STRATEN PER THOR
发明人： ANDERSEN MADS HALD , STRATEN PER THOR
IPC分类号： A61K39/00 , A61K38/00 , C07K7/00
CPC分类号： A61K39/0011 , A61K38/00 , C07K14/4702 , C07K14/82 , C12N9/14 , C12Y306/05
摘要： The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or peptides derived thereof or RhoC specific T-cells for treatment of metastatic cancer. Hence, the invention in one aspect relates to RhoC specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. Also the use of RhoC and immunogenic peptide fragments hereof in cancer treatment, diagnosis and prognosis is provided.
摘要翻译：本发明一般涉及转移性癌症的预防和治疗领域。特别是提供蛋白质; Ras同源基因家族，成员C（RhoC）或其能够引发抗癌免疫应答的肽片段。具体地，本发明涉及RhoC或其衍生的肽或RhoC特异性T细胞用于治疗转移性癌症的用途。因此，本发明在一个方面涉及通过疫苗接种转移或诱导的RhoC特异性T细胞作为癌症的治疗。还提供了在癌症治疗，诊断和预后中使用RhoC和免疫原性肽片段。

10. 发明申请

WO2009076966A2 RHOC-BASED IMMUNOTHERAPY 审中-公开
标题翻译：基于RHOC的免疫治疗
公开(公告)号：WO2009076966A2
公开(公告)日：2009-06-25
申请号：PCT/DK2008/050324
申请日：2008-12-18
申请人： RHOVAC APS , ANDERSEN, Mads Hald , STRATEN, Per Thor
发明人： ANDERSEN, Mads Hald , STRATEN, Per Thor
IPC分类号： A61K39/00 , C07K7/00 , A61K38/00
CPC分类号： A61K39/0011 , A61K38/00 , C07K14/4702 , C07K14/82 , C12N9/14 , C12Y306/05
摘要： The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or peptides derived thereof or RhoC specific T-cells for treatment of metastatic cancer. Hence, the invention in one aspect relates to RhoC specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. Also the use of RhoC and immunogenic peptide fragments hereof in cancer treatment, diagnosis and prognosis is provided.
摘要翻译：本发明一般涉及转移性癌症的预防和治疗领域。特别是提供蛋白质; Ras同源基因家族，成员C（RhoC）或其能够引发抗癌免疫应答的肽片段。具体地，本发明涉及RhoC或其衍生的肽或RhoC特异性T细胞用于治疗转移性癌症的用途。因此，本发明在一个方面涉及通过疫苗接种过继转移或诱导的RhoC特异性T细胞作为癌症的治疗。还提供了在癌症治疗，诊断和预后中使用RhoC和免疫原性肽片段。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式